Fulcrum Therapeutics (FULC) Research & Development (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Research & Development data on file, last reported at $14.1 million in Q1 2026.

• On a quarterly basis, Research & Development rose 5.07% year-over-year to $14.1 million in Q1 2026; TTM through Mar 2026 was $56.8 million, a 0.41% change from a year earlier, with the FY2025 full-year figure at $56.1 million, down 11.49% from the prior year.
• Research & Development for Q1 2026 stood at $14.1 million, down from $15.4 million in the prior quarter.
• Over the last five years, Research & Development for FULC reached as high as $25.0 million in Q2 2022 and fell as low as $11.7 million in Q4 2024.
• Historically, Research & Development has averaged $16.6 million across 5 years, with a median of $16.7 million in 2023.
• Across the five-year window, Research & Development jumped 43.97% in 2022 and slumped 38.35% in 2024, its largest moves.
• Year by year, Research & Development stood at $18.6 million in 2022, then gained by 2.33% to $19.0 million in 2023, then slumped by 38.35% to $11.7 million in 2024, then jumped by 31.61% to $15.4 million in 2025, then dropped by 8.64% to $14.1 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.1 million in Q1 2026, $15.4 million in Q4 2025, and $14.3 million in Q3 2025.